文献速递治疗药物监测与药物基因组学

伊马替尼一线治疗胃肠道间质瘤的剂量优化:成本效果研究

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
PubMed 文献 · Br J Clin Pharmacol · 2019-07-17

该研究构建5年生存模型,比较固定剂量与治疗药物监测(TDM)指导剂量对转移性/不可切除胃肠道间质瘤(GIST)患者的成本效果。结论提示TDM指导剂量可能具有成本效果。

要点

  • 固定剂量下仅约40%患者达到治疗窗内血浆浓度。
  • TDM指导剂量增加0.74 QALY(95%CI 0.66-0.90)。

核心结论

  • 基于现有数据,TDM指导剂量对转移性/不可切除GIST患者可能具有成本效果。

研究设计与样本

  • 构建生存模型模拟5年时间范围内的进展、死亡和治疗成本,比较固定剂量与TDM指导剂量。

主要发现

  • TDM指导剂量较固定剂量增加0.74 QALY(95%CI 0.66-0.90)。

关键数值与推荐

  • 固定剂量下仅约40%患者达到治疗窗内血浆浓度。

临床怎么用

  • 对转移性/不可切除GIST一线伊马替尼治疗患者,可考虑采用TDM指导剂量以优化血浆浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Patients with metastatic gastrointestinal stromal tumours (GIST) are treated in first line with the oral tyrosine kinase inhibitor, imatinib, until progressive disease. With this fixed dosing regimen, only approximately 40% of patients reach adequate plasma levels within the therapeutic index. Therapeutic drug monitoring (TDM) is a solution to reach plasma levels within the therapeutic index. However, introducing TDM will also increase costs, due to prolonged imatinib use and laboratory costs. The aim of this study was to evaluate the cost-effectiveness of TDM in patients with metastatic/unresectable GIST treated with imatinib as a first line treatment, compared with fixed dosing. METHODS: A survival model was created to simulate progression, mortality and treatment costs over a 5-year time horizon, comparing fixed dosing vs TDM-guided dosing. The outcomes measured were treatments costs, life-years and quality-adjusted life-years. RESULTS: Total costs over the 5-year time horizon were estimated to be €106 994.85 and €150 477.08 for fixed dosing vs TDM-guided dosing, respectively. A quality-adjusted life year gain of 0.74 (95% confidence interval 0.66-0.90) was estimated with TDM-guided dosing compared to fixed dosing. An average incremental cost-effectiveness ratio of €58 785.70 per quality-adjusted life year gained was found, mainly caused by longer use and higher dosages of imatinib. CONCLUSION: Based on the currently available data, this analysis suggests that TDM-guided dosing may be a cost-effective intervention for patients with metastatic/unresectable GIST treated with imatinib which will be improved when imatinib losses its patency.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zuidema S, Desar IME, van Erp NP, et al. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study. Br J Clin Pharmacol. 2019. PMID: 31112617. doi:10.1111/bcp.13990

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。